You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. MOTAR STRATFI

    SBC: DYNEPIC, INC.            Topic: J201CSO1

    Dynepic’s STRATFI solution continues the efforts of the completed Phase II SBIR to continue, extend, scale and enhance the features and capabilities of MOTAR. STRATFI funding provides the remaining core capabilities to make MOTAR a viable and sustainable XR ecosystem. MOTAR provides a secure digital infrastructure to save time and money to deliver a platform with the critical capabilities requir ...

    SBIR Phase II 2023 Department of DefenseAir Force
  2. Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke

    SBC: TRANSLATIONAL SCIENCES INC            Topic: 103

    Ischemic stroke is the second leading cause of death and disability worldwide. Tissue plasminogen activator (TPA), the only approved treatment for ischemic stroke, dissolves the culprit fibrin thrombus to restore blood flow and relieve the brain from ischemia. Unfortunately, after prolonged ischemia, TPA restores full blood flow in only 30% of patients and may cause serious or fatal complications; ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

    SBC: IMMUNO TECHNOLOGIES INC            Topic: R

    DESCRIPTION Caused by Borrelia burgdorferi Lyme disease LD can affect the skin heart joints or nervous system leading to an array of largely non specific symptoms that overlap with those of other debilitating illnesses Disease progression can lead to development of conditions with unfavorable prognosis such as antibiotic refractory arthritis or Post Treatment Lyme disease Syndrome PTLDS ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Reducing Stroke by a Novel, Clot-dissolving Antibody

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NINDS

    DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death and the primary cause of severe, long term disability. Each year 795,000 Americans have a stroke and the annual costs to the economy are 57.9 billion. The vast majority of acute ischemic strokes are caused by a thrombus (blood clot) which occludes the blood vessel and stops blood flow to the brain. Tissue plasminogen a ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Computerized Adaptive Assessment of Disease Impact

    SBC: QUALITYMETRIC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This SBIR Phase II project will develop and evaluate a more practical and comprehensive approach to standardizing the self-assessment of disease-specific Health-Related Quality of Life (HRQOL) in the growing population of aging (45+ years) adults with, and at-risk of, co-morbid chronic conditions. Specifically, we propose to simplify disease impact screening (f ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    Each year venous thromboembolism affects up to 2 million Americans and 24 million people worldwide. Patients with venous thromboembolism have blood clots in the legs (venous thrombosis) that may travel to the lungs (pulmonary embolism). Pulmonary embolism (PE) is a leading cause of hospital deaths. Pulmonary emboli may acutely obstruct blood flow, causing right heart failure, circulatory collapse ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A Universal Brain Atlas for Implanting and Managing Deep Brain Stimulators

    SBC: Neurotargeting, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Deep brain stimulation has risen as a neurosurgical procedure of choice for patients with disabling neurological or psychiatric disorders for its abiliy to modulate improvement in the activity of certain circuits. The procedure is currently approved for treatment of Parkinson's disease (PD), essential tremor (ET), dystonia, and obsessive-compulsive disorde ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Role of Inter-alpha Inhibitors in Anthrax Intoxication

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Anthrax is recognized as a class A bio-threat microbial pathogen that is readily weaponized and exceedingly difficult to treat. This bacterium is highly virulent inducing lethal infection in immunologically normal hosts by its intrinsic capacity to disseminate rapidly and induce sepsis, along with its ability to generate two highly potent exotoxins, lethal toxi ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government